HDAC9 and cancer: Romidepsin, an FDA‐approved drug with multiple cancer indications, acts as an inhibitor of Class I histone deacetylases (HDAC) [19], while interferon α2b was among the first drugs developed specifically for melanoma treatment, activating a transcriptional program that exhibits anti‐cancer activity [20].